Pyrotinib

Pre-clinicalUNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 22/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

HER2-positive Breast Cancer

Conditions

HER2-positive Breast Cancer

Trial Timeline

Oct 1, 2022 → Oct 1, 2025

NCT ID

NCT05561686

About Pyrotinib

Pyrotinib is a pre-clinical stage product being developed by Jiangsu Hengrui Medicine for HER2-positive Breast Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT05561686. Target conditions include HER2-positive Breast Cancer.

What happened to similar drugs?

0 of 15 similar drugs in HER2-positive Breast Cancer were approved

Approved (0) Terminated (0) Active (15)

🔄TrastuzumabCelltrionPhase 3

🔄Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3

🔄Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + TrastuzumabDaiichi SankyoPhase 3

🔄DS-8201a + T-DM1Daiichi SankyoPhase 3

🔄SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel InjectionJiangsu Hengrui MedicinePhase 3

🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3

🔄Pyrotinib + Placebo Oral Tablet + Trastuzumab + DocetaxelJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05834764	Phase 2	Recruiting	Apr 8, 2023	Dec 31, 2028	HER2-positive Breast Cancer
NCT05561686	Pre-clinical	UNKNOWN	Oct 1, 2022	Oct 1, 2025	HER2-positive Breast Cancer
NCT04179656	Phase 2	UNKNOWN	Dec 1, 2019	Dec 1, 2022	Solid Tumor
NCT02834936	Phase 2	Completed	Oct 20, 2016	Jun 20, 2019	Non Small Cell Lung
NCT01937689	Phase 1	Completed	Jan 1, 2013	Dec 1, 2016	Breast Cancer

Competing Products

20 competing products in HER2-positive Breast Cancer

See all competitors

Product	Company	Stage	Hype Score
ALT-P7 (HM2-MMAE)	Alteogen	Phase 1	29
CT-0508 + Pembrolizumab	Carisma Therapeutics	Phase 1	23
CT-0525	Carisma Therapeutics	Phase 1	23
Trastuzumab	Celltrion	Phase 3	40
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + Gemcitabine	Chugai Pharmaceutical	Phase 3	40
YH32367	Yuhan	Phase 1/2	39
Trastuzumab deruxtecan	Daiichi Sankyo	Pre-clinical	33
Trastuzumab deruxtecan	Daiichi Sankyo	Pre-clinical	26
Trastuzumab deruxtecan	Daiichi Sankyo	Pre-clinical	33
Trastuzumab deruxtecan (T-DXd)	Daiichi Sankyo	Pre-clinical	33
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	42
Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + Trastuzumab	Daiichi Sankyo	Phase 3	44
DS-8201a + T-DM1	Daiichi Sankyo	Phase 3	44
Pertuzumab + Trastuzumab + eribulin	Eisai	Phase 2	27
Tucatinib 150 MG + Trastuzumab + Capecitabine	Biocon	Phase 2	42
SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection	Jiangsu Hengrui Medicine	Phase 3	44
SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab Injection	Jiangsu Hengrui Medicine	Phase 3	47
Pyrotinib + Placebo Oral Tablet + Trastuzumab + Docetaxel	Jiangsu Hengrui Medicine	Phase 3	40
SHR-A1811 + Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan	Jiangsu Hengrui Medicine	Phase 3	47
pyrotinib tablet + Montmorillonite Power + Loperamide	Jiangsu Hengrui Medicine	Phase 1	29